Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q2 2025 (June 30)15holders −2
2new positions
4sold out
$2.20avg. 13F price*
At the end of Q2 2025, 15 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, down 2 from Q1 2025. 2 opened new positions and 4 sold out. The largest holders were Nomura Holdings Inc. ($15.9M), Sonora Investment Management Group, LLC ($4.0M) and New York State Common Retirement Fund ($3.2M).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2.0M |
| Exits | 4 | $143K |
All 13F filers, Q1 2025 → Q2 2025: 2,228,478 shares bought and 497,057 shares sold, net +1,731,421 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Nomura Holdings Inc. | 0.13% | Add +4.2% | 305,464 | $15.9M |
| Sonora Investment Management Group, LLC | 0.30% | Reduce -0.3% | 4,027,000 | $4.0M |
| New York State Common Retirement Fund | 0.00% | Add +5.0% | 3,216,000 | $3.2M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 2,650,000 | $2.6M |
| State of Wisconsin Investment Board | 0.00% | New | 2,000,000 | $2.0M |
| Bank of New York Mellon Corp | 0.00% | Reduce -50.0% | 300,000 | $299K |
| &partners | 0.00% | Reduce -1.4% | 138,000 | $137K |
| Cetera Investment Advisers | 0.00% | Reduce -26.3% | 126,000 | $125K |
| Mariner, LLC | 0.00% | No change | 54,000 | $54K |
| Cerity Partners LLC | 0.00% | New | 43,000 | $43K |
| Boussard & Gavaudan Investment Management LLP | 0.01% | Add +134.7% | 35,200 | $35K |
| Choreo, LLC | 0.00% | No change | 28,000 | $28K |
| MAI Capital Management | 0.00% | Reduce -21.1% | 15,000 | $15K |
| Comerica Bank | 0.00% | No change | 10,000 | $10K |
| Laffer Tengler Investments, Inc. | 0.00% | Reduce -2.8% | 1,984 | $2K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.